Regeneron Pharmaceuticals and Sanofi are pulling their supplemental Biologics License Application (sBLA) for the indication of cervical cancer for their human monoclonal antibody, Libtayo (cemiplimab-rwlc). Source: Drug Industry Daily
The U.S. International Trade Commission (ITC) will investigate whether Alvotech and its partner Teva Pharmaceuticals misappropriated trade secrets in producing a biosimilar candidate for AbbVie’s autoimmune mega-blockbuster Humira (adalimumab). Source:…
Eli Lilly has given up on its blockbuster rheumatoid arthritis drug Olumiant as a treatment for lupus. Source: Drug Industry Daily
Michigan’s Attorney General is pursuing court approval to begin an investigation into Eli Lilly over the high insulin prices the company charges. Source: Drug Industry Daily
Protection against Omicron-related death in people 50 and older reached as high as 95 percent after a booster dose of a messenger RNA (mRNA) vaccine, the UK Health Security Agency…
Merck’s Keytruda (pembrolizumab) has made a couple of headlines this week, drawing attention as a potential weapon against latent HIV infections, and winning approval in Europe as a kidney cancer…
Prominent industry figures have praised the FDA’s recent draft guidance on using electronic health records (EHRs) and medical claims data in trials, but they hope it will acknowledge issues inherent…
Immunocore’s Kimmtrak (tebentafusp-tebn) has won FDA approval for treating inoperable or metastatic uveal melanoma, a rare adult eye cancer with poor prognosis. Source: Drug Industry Daily
Researchers from the University of Minnesota and 46brooklyn Research have shown in a new analysis that prices of entecavir, a generic drug that’s one of the first-line treatments used to…
A number of academic and medical institutions are still not reporting their trial results as required by federal law, a new analysis shows. Source: Drug Industry Daily